Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Stadler

Showing results (581-590 of 724) with videos related to

Pageof 73
Sort By:
The Review of Scientific Instruments|April 4, 2023
Multi-angle in situ dynamic light scattering at a neutron spin echo spectrometerF Vögl, L Balacescu, O Holderer, et al.
Journal of Clinical Pharmacology|April 5, 2013
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysisBrian I Rini, May Garrett, Bill Poland, et al.
American Journal of Clinical Oncology|August 8, 2012
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinomaMark C Ranck, Daniel W Golden, Kimberly S Corbin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75Noah M Hahn, Walter M Stadler, Robin T Zon, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|February 22, 2013
Is there a benefit to use calculated percent body fat or age- and gender-adjusted BMI-SDS(LMS) to predict risk factors for cardiovascular disease? A German/Austrian multicenter DPV-Wiss analysis on 42 048 type 2 diabetic patientsN Scheuing, C Bayer, F Best, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2019
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelR Chugh, K A Griffith, E J Davis, et al.
Journal of Biotechnology|January 26, 1996
Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection modelA Hensel, L A van Leengoed, M Szostak, et al.
Cancers|November 9, 2024
Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia NetworkSeyedeh Sadaf Asfa, Reza Arshinchi Bonab, Onur Önder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancerHedy L Kindler, Gregory Friberg, Deepti A Singh, et al.
Urologic Oncology|September 22, 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)Andrew J Armstrong, Reza Kaboteh, Michael A Carducci, et al.
Pageof 73

Showing results (581-590 of 724) with videos related to

Sort By:
Pageof 73
The Review of Scientific Instruments|April 4, 2023
Multi-angle in situ dynamic light scattering at a neutron spin echo spectrometerF Vögl, L Balacescu, O Holderer, et al.
Journal of Clinical Pharmacology|April 5, 2013
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysisBrian I Rini, May Garrett, Bill Poland, et al.
American Journal of Clinical Oncology|August 8, 2012
Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinomaMark C Ranck, Daniel W Golden, Kimberly S Corbin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75Noah M Hahn, Walter M Stadler, Robin T Zon, et al.
Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [And] German Diabetes Association|February 22, 2013
Is there a benefit to use calculated percent body fat or age- and gender-adjusted BMI-SDS(LMS) to predict risk factors for cardiovascular disease? A German/Austrian multicenter DPV-Wiss analysis on 42 048 type 2 diabetic patientsN Scheuing, C Bayer, F Best, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 7, 2019
Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM modelR Chugh, K A Griffith, E J Davis, et al.
Journal of Biotechnology|January 26, 1996
Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection modelA Hensel, L A van Leengoed, M Szostak, et al.
Cancers|November 9, 2024
Computer-Aided Identification and Design of Ligands for Multi-Targeting Inhibition of a Molecular Acute Myeloid Leukemia NetworkSeyedeh Sadaf Asfa, Reza Arshinchi Bonab, Onur Önder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancerHedy L Kindler, Gregory Friberg, Deepti A Singh, et al.
Urologic Oncology|September 22, 2014
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC)Andrew J Armstrong, Reza Kaboteh, Michael A Carducci, et al.
Pageof 73